News & Views

  • Agreement to Advance Preclinical Services
    Eric Rhodes

Agreement to Advance Preclinical Services

Oct 22 2020 Read 348 Times

US Biotech Applied StemCell, has signed a licencing agreement with Dublin-based ERS Genomics for use of its CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, for developing its preclinical research tools, including cell and animal model generation, antibody discovery and preclinical assay services to support cell and gene product development.

“Applied StemCell has been a leading stem cell company I have followed for many years," said Eric Rhodes, CEO of ERS Genomics. “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."

“We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,” added Ruby Tsai, CEO of Applied StemCell.

Financial details of the agreement were not disclosed.

More information online 

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Lab Asia December 2020

December 2020

In This Edition Articles - The Movement Towards More Comprehensive Testing of Mycotoxins in Cannabis - Addressing proper HACCP implementation - Micropatterning: The art of micro-controlling...

View all digital editions



Dec 08 2020 Beijing, China


Dec 08 2020 VIrtual event

Nano Tech 2021 - NEW DATES

Dec 09 2020 Tokyo, Japan

Medical Fair Asia 2020 - NEW DATES

Dec 09 2020 Virtual event

View all events